EVALUATION OF QUALITY OF LIFE INDICATORS IN NSTEMI PATIENTS DEPENDING ON PLASMA LEVEL ST2, NATURE OF CORONARY ARTERIES LESION AND OTHER CLINICAL CHARACTERISTICS
DOI:
https://doi.org/10.11603/mcch.2410-681X.2021.i4.12673Keywords:
NSTEMI, quality of life, ST2, coronary arteriesAbstract
Introduction. The prevalence of myocardial infarction and its leading role in the structure of overall and cardiovascular mortality encourages the search for predictors of adverse disease and the search for optimal means to prevent adverse events and improve the quality of life of this category of patients.
The aim of the study – to evaluate quality of life in NSTEMI patients based on plasma ST2 levels, the nature of coronary artery disease, and other clinical characteristics.
Research Methods. The study involved 200 patients with NSTEMI aged 38 to 80 years. All patients were examined according to the current treatment protocol for patients with acute myocardial infarction without ST segment elevation, plasma ST2 levels were determined and quality of life was assessed using the MIDAS-35 questionnaire.
Results and Discussion. Spearman's rank correlation showed that the level of physical activity (the first subscale of MIDAS-35) of patients with NSTEMI is directly correlated with the presence of frequent ventricular extrasystoles and paroxysms of ventricular tachycardia recorded during ECG monitoring on day 1 of NSTEMI, the severity of coronary artery lesions and plasma ST2 levels determined on the 1st day of hospitalization. Similar patterns are found in subscales 2, 4, 5. Subscale 6 revealed the presence of a correlation only with the presence of frequent ventricular tachycardia. Subscales 3 and 7 did not show correlations with the studied parameters.
Conclusions. Elevated ST2 levels, hemodynamically significant coronary artery lesions and the presence of acute arrhythmias in the early period of NSTEMI have been found to significantly affect quality of life as determined by the MIDAS-35 questionnaire. The impact on remodeling processes and the strategy of early invasive treatment in patients with NSTEMI will not only reduce the likelihood of complications, but also improve the quality of life of this category of patients.
References
van Vark, L.C., Lesman-Leegte, I., Baart, S.J., Postmus, D., Pinto, Y.M., Orsel, J.G., …, & Akkerhuis, K.M. (2017). Prognostic value of serial ST2 measurements in patients with acute heart failure. J. Am. Coll. Cardiol., 70 (19), 2378-2388. DOI: 10.1016/j.jacc.2017. 09.026.
Bayes-Genis, A., de Antonio, M., Vila, J., Peñafiel, J., Galán, A., Barallat, J., ..., & Lupón, J. (2014). Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification. J. Am. Coll. Cardiol., 63 (2), 158-166. DOI: 10.1016/j.jacc.2013.07.087.
Villacorta, H., & Maisel, A.S. (2016). Soluble ST2 testing: promising biomarker in the management of heart failure. Arq. Bras. Cardiol., 106 (2), 145-152. DOI: 10.5935/ abc.20150151.
Collet, J.P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D.L., …, & Siontis, G.C.M. (2021). 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J., 42 (14), 1289-1367. DOI: 10.1093/eurheartj/ehaa575.
Mueller, T., & Dieplinger, B. (2013). The Presage®ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Exp. Rev. Mol. Diagn., 13 (1), 13-30. DOI: 10.1586/erm.12.128.
Guo, C., Feng, S., Chen, Y., & Liu, M. (2020). Application of quality nursing care for interventional therapy in myocardial infarction for improving the quality of life of patients. Int. J. Clin. Exp. Med., 13 (4), 2565-2572.
Ivanov, V., Mezhievska, I., & Maslovskyi, V. (2020). Characteristics of anatomic injury of coronary arteries in patients with acute myocardial infarction without ST elevation depending on plasma level of gene 2 growth stimulating factor and risk of adverse events. Acta Medica Leopoliensia, 26 (1), 20-25.
Thompson, D.R., & Watson, R. (2011). Mokken scaling of the Myocardial Infarction Dimensional Assessment Scale (MIDAS). J. Eval. Clin. Pract., 17 (1), 156-159. DOI: 10.1111/j.1365-2753.2010.01415.x.
Thompson, D.R., Jenkinson, C., Roebuck, A., Lewin, R.J., Boyle, R.M., & Chandola, T. (2002). Development and validation of a short measure of health status for individuals with acute myocardial infarction: the myocardial infarction dimensional assessment scale (MIDAS). Qual. Life Res., 11 (6), 535-543. DOI: 10.1023/ a:1016354516168.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Medical and Clinical Chemistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
